Disc Medicine
Dr. Rivella has a long-term expertise in the pathophysiology and genetics of several disease of hematopoiesis-, inflammation-, and iron-related disorders as well as in the use of new drugs for for the cure of hemoglobinopathies. He characterized the role of seminal factors contributing to the morbidity and mortality in ß-thalassemia, sickle cell anemia, Polycythemia vera, hemochromatosis and in anemia of inflammation, such as such hepcidin, intereleukin-2 and ferroportin, the phosphokinase Jak2 and macrophages. For his research, Dr. Rivella has been awarded the New Investigator Award at the International Society of Experimental Hematology, the Sultan bin Khalifa International Thalassemia Federation Award, the Marcel Simon Award from the International BioIron Society (IBIS), numerous travel and fellowship awards from several international scientific societies, grants from the Cooley’s Anemia Foundation, Roche Foundation for Anemia Research (RoFAR) and 8 grants from the National Institutes of Health (NIH) as a PI.
This person is not in the org chart
This person is not in any offices
Disc Medicine
Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. Disc Medicine is building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.